|
| 丹参酮Ⅱ A对生长期大鼠骨密度及骨形态计量学影响的研究 |
| The effect of tanshinone IIA on bone mineral density and bone morphology in growing rats |
| |
| DOI：10.3969/j.issn.1006.7108.2017.11.016 |
| 中文关键词: 丹参酮ⅡA 骨密度 骨形态 大鼠 动物实验 |
| 英文关键词:Tanshinone II A Bone mineral density Histomorphometry Rats Animal experimentation |
| 基金项目:国家自然科学基金（81471090) |
|
| 摘要点击次数: 747 |
| 全文下载次数: 567 |
| 中文摘要: |
| 目的 研究丹参酮ⅡA对生长期大鼠骨密度及骨形态的影响，并探讨其可能的机制，对其预防与治疗骨质疏松症的疗效作出初步判断。方法 1月龄雌性Wistar大鼠30只，随机分为丹参酮ⅡA组[11 mg/(kg ? d)，n= 10]、淫羊藿苷组[阳性对照，25 mg/(kg ? d), n = 10]和正常对照组（相同体积蒸馏水，n = 10)。每两周称取一次体重，每月用双能X射线骨密度仪检测全身骨密度;若组间全身骨密度差异有统计学意义，处死所有实验动物。测定椎骨和右侧股骨的离体骨密度；品红-苦味酸染色（van-gieson，VG)进行骨形态分析;ELISA法检测血清抗酒石酸性磷酸酶5b(TRACP 5b)和骨钙素（osteocalcin，OC)的水平。 结果 大鼠的体重比较差异无统计学意义（P >0.05);第1个月全身骨密度无明显差异（P >0.05)，第2个月给药组全身骨密度均显著髙于对照组，与对照组相比，丹参酮ⅡA组和淫羊藿苷组大鼠全身骨密度、椎骨骨密度、股骨骨密度、骨小梁数目、骨小梁厚度、骨小梁面积和血清OC均有所增加，差异均有统计学意义（P <0.05);而骨小梁间隙和血清TRACP 5b均减小，差异 具有统计学意义（P <0.05)。丹参酮ⅡA组和淫羊藿苷组差异没有统计学意义(P >0.05)。结论丹参酮ⅡA可通过提髙大鼠骨密度及骨质量来预防与治疗OP，对探索抗骨质疏松中药单体新药有非常重要的意义。 |
| 英文摘要: |
| Objective To study the effect of tanshinone ⅡA on bone mineral density (BMD) and bone morphology in growing rats，and to explore its possible mechanism and clinical efficacy. Methods Thirty 6-week-old female Wistar rats were randomly divided into tanshinone ⅡA group (11 mg/(kg ? d)，n =10)，epimedium glycoside group (positive control，25 mg/(kg ? d)，n = 10)， and normal control group (the same volume of distilled water，n = 10). The weight was monitored every two weeks. BMD of the whole body was detected with dual-energy X-ray bone density (DEXA) per month. When the whole-body BMD between the groups was statistically significant，all the experimental rats were killed. BMD of the vertebrae and right femurs was determined ex vivo. Bone morphology was analyzed after Fuchsin picric acid staining (van Gieson，VG). The levels of tartaric acid phosphatase 5b (TRACP 5b) and osteocalcin (OC) were measured with ELISA method . Results There was no statistical significance of weight in rats (P >0.05). BMD of the whole body was no obvious difference at the first month (P >0.05). It was significantly higher in drug administered groups than that in control group after 2 months. Comparing to those in control group，BMD of the whole body，the vertebrae，and the femurs， trabecular bone number，trabecular thickness，trabecular bone area，and OC in tanshinone ⅡA and epimedium glycoside groups increased, but the trabecular bone gap and TRACP 5b reduced significantly (P <0. 05). There was no statistical difference between tanshinone II A and epimedium glycoside group (P >0. 05). Conclusion Tanshinone II A prevents and treats osteoporosis by improving BMD and bone quality in rats. It has very important significance in investigation of anti?osteoporosis Chinese medicine monomers. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |